Drug Discovery Software Specialists Combine Expertise

A collaborative partnership between Optibrium™ and Lhasa Limited is researching into next generation drug metabolism modelling, with findings made available to both organisations in the development of future products with improved and extended metabolism prediction capabilities.

The research project has appointed Dr Mario Öeren as Senior Scientist to lead the study and work with a team of scientists from both Lhasa and Optibrium. As a theoretical chemist who has specialised in computational chemistry, Mario has a PhD in Natural Sciences from Tallinn University of Technology, Estonia where he has since worked as a researcher and lecturer. Mario will be based at Optibrium’s headquarters in Cambridge, UK.

Dr. Matt Segall, CEO at Optibrium said: “This R&D collaboration with Lhasa builds on a long-standing relationship and is part of our continued investment in the development of novel technologies to improve efficiency in drug discovery. We welcome Mario to the team and look forward to extending the metabolism modelling capabilities within our combined product portfolio for the mutual benefit of Lhasa members and StarDrop users.”

Dr. Chris Barber, Director of Science at Lhasa added: “We are excited by the complementary approaches that Lhasa and Optibrium have applied in the past with Lhasa capitalising on data donated by its member organisations and Optibrium applying theoretical approaches. Both approaches have their advantages but combining and applying them across all stages of development should allow us to provide real benefit to the end user.”

In StarDrop, Optibrium has developed a comprehensive suite of integrated software with a highly visual and user-friendly interface. Lhasa specialises in the development of transparent in silico models together with supporting databases in the fields of toxicology, metabolism, degradation and organic synthesis.